Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Funapide - Flexion Therapeutics

Drug Profile

Funapide - Flexion Therapeutics

Alternative Names: FX301; TV-45070; XEN 402; XPF 001; XPF-002

Latest Information Update: 11 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xenon Pharmaceuticals
  • Developer Flexion Therapeutics; Teva Pharmaceutical Industries; Xenon Pharmaceuticals
  • Class Benzodioxoles; Fluorobenzenes; Furans; Indoles; Non-opioid analgesics; Small molecules; Spiro compounds
  • Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors; Nav1.8 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Erythromelalgia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuropathic pain; Postherpetic neuralgia
  • Preclinical Postoperative pain
  • Discontinued Dental pain; Erythromelalgia; Musculoskeletal pain; Pain

Most Recent Events

  • 09 Sep 2019 Flexion Therapeutics plans a clinical trial for Postoperative pain in 2021 (Parenteral,Controlled release)
  • 09 Sep 2019 Flexion Therapeutics plans a phase II proof-of-concept trial for Postoperative pain in 2021 (Parenteral,Controlled release)
  • 09 Sep 2019 Flexion Therapeutics acquires Funapide from Xenon Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top